Company Overview and News

 
Introduction of new taxes could further impact property sector, says TA Securities

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): Any introduction of new taxes — such as the inheritance tax and capital gain tax — could weigh on house buyers and investor sentiment, further impacting the property sector which has already been plagued by affordability and strict lending issues, according to TA Securities.
5249 5062 GLOCF

 
Finology eyes top developers for its credit, loan-scoring services

2018-09-03 thestar.com.my
“We are holding ongoing discussions at a senior level with several key players in Government Affordable Housing, and there are positive signals indicating that our Loanplus Services will be utilized by many leading Affordable Housing in Malaysia, including Prima and Syarikat Perumahan Negara Bhd (SPNB),” said Finology Sdn Bhd founder Jared Lim (pic).
5062

 
Hua Yang to maintain sales target of RM400m in FY19

2018-08-29 theedgemarkets
KUALA LUMPUR (Aug 29): Property developer Hua Yang Bhd is maintaining last year’s target sales of RM400 million for the financial year ending March 31, 2019 (FY19).
5062

 
Hua Yang seen to perform better in coming quarters

2018-07-20 theedgemarkets
Hua Yang Bhd (July 19, 46 sen) Maintain market perform with an unchanged target price of 46.5 sen: Although only making up 10% and 12% of our and consensus full-year estimates, we deem Hua Yang Bhd’s first quarter ended June 30, 2018 (1QFY19) results to be in line as we are banking on a stronger performance in subsequent quarters, backed by better sales, progressive billings and normalised effective tax rate by the second half of FY19 (2HFY19).
5062

 
Hua Yang dips 3.23% as 1Q earnings fall 45%

2018-07-19 theedgemarkets
KUALA LUMPUR (July 19): Shares of property developer Hua Yang Bhd dipped 3.23% this morning after its net profit declined 45.5% to RM1.01 million or 0.29 sen per share in its first quarter ended June 30, 2018, from RM1.86 million or 0.53 sen per share a year ago, owing to higher finance costs.
5062

 
Trading ideas: Ranhill, Hua Yang, Ikhmas Jaya, Tek Seng

2018-07-19 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Ranhill Holdings Bhd , Hua Yang Bhd , Ikhmas Jaya Group Bhd and Tek Seng Holdings Bhd to be among the stocks to watch following their latest news.
5062 5272 5268 7200

 
KLCI to trend higher, immediate hurdle at 1,755

2018-07-18 theedgemarkets
KUALA LUMPUR (July 19): The FBM KLCI is expected to trend higher today, tracking the overnight gains at most global markets, with immediate hurdle at 1,755 points.
7073 0101 5062 6459 5272 5268 7200

 
Maxis, Seacera, Sapura Energy, MNRB, TMC Life Sciences, Ranhill, Hua Yang, Ikhmas Jaya, Menang Corp and Tek Seng

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (July 19) may include the following: Maxis Bhd, Seacera Group Bhd, Sapura Energy Bhd, MNRB Holdings Bhd, TMC Life Sciences Bhd, Ranhill Holdings Bhd, Hua Yang Bhd, Ikhmas Jaya Group Bhd, Menang Corp (M) Bhd and Tek Seng Holdings Bhd.
7073 0101 5062 6459 5272 BSMAF 5268 7200 1818

 
Hua Yang 1Q earnings decline 46% on higher finance cost

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): Property developer Hua Yang Bhd registered a decline in earnings of 45.5% to RM1.01 million in its first quarter ended June 30 from RM1.86 million a year ago, owing to higher finance costs.
5062

2
Trading ideas: Destini, AAX, UMW, Inari, Serba Dinamik, TM

2018-05-23 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Destini Bhd , AirAsia X Bhd (AAX), UMW Holdings Bhd , Inari Amerton Bhd, Serba Dinamik Holdings Bhd and Telekom Malaysia Bhd (TM) to be among the stocks to watch on Wednesday.
5238 4588 4863 5062 MYTEF

 
Finology-Tropicana tie-up likely

2018-04-16 thestar.com.my
When contacted, Finology founder Jared Lim(file pic) confirmed that it is working with Tropicana to develop automated processes to prepare for a roll out of the latter’s projects.
5062

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...